Contact us at 1.800.501.7654 or info@biossusa.com
Bioss Resources
Browse research updates, product guides, grant news, and practical antibody workflow articles from Bioss.
A scientific perspective vividly describes proteins as locks and small-molecule activators or inhibitors as perfectly matched keys— they insert, turn, or jam the lock, thereby controlling the entire machinery of life. This metaphor, rooted in the classic "lock-and-key model" proposed by Emil...
Read more
For years, Alzheimer’s disease (AD) has remained a formidable challenge for patients, families, and researchers. One of the most heartbreaking realities for many is the phrase: “There is no cure.” Although several new treatments have emerged over the past few decades, options...
Read more
Alzheimer’s disease (AD) remains a devastating challenge, robbing millions worldwide of their memories and independence. For decades, treatments only addressed symptoms—until now. Enter Kisunla (donanemab-azbt), a groundbreaking therapy from Eli Lilly that targets the root cause of AD: toxic amyloid plaques in...
Read more
The story of bispecific antibodies teaches us that biomedical innovation often stems from deep understanding and creative adaptation of natural mechanisms. Just as the immune system itself is a masterful "multispecific" recognition network, scientists have mimicked and expanded upon it to unlock...
Read more
This article provides a comprehensive overview of Small molecule-conjugated carrier Proteins (SM-CCPs), integrating their construction, applications, advantages, challenges, and future directions to offer readers an in-depth scientific perspective.
Read more
Research-grade in vivo biosimilar antibodies provide a critical tool for scientists studying therapeutic mechanisms in disease models. Their high demand is fueled by the rapid growth of biopharmaceutical research, the need for cost-effective alternatives to commercial antibodies, and the expansion of immuno-oncology,...
Read more
A study in The Journal of Clinical Investigation by George C. Tskokos and his team at Beth Israel Deaconess Medical Center demonstrates that Calcium/Calmodulin-Dependent Protein Kinase IV (CaMK4) is overexpressed in injured podocytes. This makes CaMK4 a promising therapeutic target for treatment...
Read more
